After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
BCYC belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Bicycle Therapeutics Plc ADR is $975.47M. A total of 0.61 million shares were traded on the day, compared to an average of 381.40K shares.
In the most recent transaction, Lee Kevin sold 3,158 shares of BCYC for 23.81 per share on Apr 03 ’24. After the transaction, the CHIEF EXECUTIVE OFFICER now owns 387,270 company shares. In a previous transaction on Apr 03 ’24, Crockett Nigel sold 955 shares at 23.81 per share. BCYC shares that CHIEF BUSINESS OFFICER owns now total 47,761.
Among the insiders who sold shares, Milnes Alistair disposed of 955 shares on Apr 03 ’24 at a per-share price of $23.81. This resulted in the CHIEF OPERATING OFFICER holding 72,241 shares of BCYC after the transaction. In another insider transaction, Skynner Michael sold 955 shares at $23.81 per share on Apr 03 ’24. Company shares held by the CHIEF TECHNOLOGY OFFICER now total 94,884.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BCYC has a high of $28.91 and a low of $12.54.
As of this writing, BCYC has an earnings estimate of -$1.24 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$1.03 per share and a lower estimate of -$1.4. The company reported an EPS of -$1.26 in the last quarter, which was -7.70% lower than expectations of -$1.17.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCYC is Buy with a score of 4.75.
